DTT + JASPER for Autism
Trial Summary
The trial requires that participants have stable medication for the past 6 months, so you should not change your current medications if you want to participate.
Research shows that JASPER, which is part of the DTT + JASPER treatment, helps improve play diversity and social interactions in children with autism. Additionally, Discrete Trial Training (DTT) has been effective in teaching language and play skills, suggesting that combining these approaches could be beneficial for children with autism.
12345The available studies on JASPER and related interventions like DTT (Discrete Trial Training) and ABA (Applied Behavior Analysis) do not report any safety concerns, suggesting these treatments are generally safe for use in children with autism.
23567The DTT + JASPER treatment is unique because it combines Discrete Trial Training (DTT), which is a structured teaching method, with JASPER, which focuses on improving joint attention and symbolic play skills. This combination targets specific developmental areas that are often delayed in children with autism, such as social interaction and play, which are not always the primary focus of other treatments.
24689Eligibility Criteria
The PRISM study is for preschoolers aged 36-59 months with Autism Spectrum Disorder who speak less than 20 functional words. They must have had over 3 months of early intervention, stable medication for the past half year, and a nonverbal mental age above one year. Children with sensory/motor impairments or genetic syndromes like Down Syndrome are not eligible.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Stage 1 Treatment
Participants receive either JASPER or DTT intervention for 10 weeks, 2 hours per week
Stage 2 Treatment
Early responders continue with the same intervention; slow responders are re-randomized to either intensify the current intervention or switch to Combined & Enhanced Treatment (CET)
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 10 weeks post-treatment and at age 6
Participant Groups
DTT is already approved in United States for the following indications:
- Autism Spectrum Disorder
- Developmental Delays